Stay updated on Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial
Sign up to get notified when there's something new on the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page.

Latest updates to the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page
- CheckyesterdayChange DetectedThe page footer now shows Revision: v3.3.4, replacing Revision: v3.3.3.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedFooter now shows Revision: v3.3.3; HHS Vulnerability Disclosure link and older Revision: v3.3.2 have been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check51 days agoChange DetectedMinor revision: updated from v3.2.0 to v3.3.2 and no changes to study details or content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check58 days agoChange DetectedRemoved the notice about government funding and potential delays. The page no longer displays operating status information.SummaryDifference0.4%

- Check72 days agoChange DetectedBetween the old and new screenshots, core trial information (title, conditions, eligibility criteria, endpoints, enrollment location, and contact) remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check101 days agoChange DetectedAdded a government funding lapse notice and a v3.2.0 version tag, replacing the prior v3.1.0.SummaryDifference5%

Stay in the know with updates to Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page.